استمتع بـUnlimited مع Magzter GOLD

استمتع بـUnlimited مع Magzter GOLD

احصل على وصول غير محدود إلى أكثر من 9000 مجلة وصحيفة وقصة مميزة مقابل

$149.99
 
$74.99/سنة

يحاول ذهب - حر

"Bridge the gap and accelerate India's advancements in innovative therapies"

BioSpectrum India Oct 2024

|

Bio Spectrum

Dr Ramesh Mundlamuri has over 19 years of experience in various biopharmaceutical organizations and has ample experience in various divisions and sections of the biopharmaceutical industry, including Research & Development, Technology Transfer, Commercial Manufacturing, Product & Process Development, Operations Management and so on.

"Bridge the gap and accelerate India's advancements in innovative therapies"

Prior to joining Duoning, he worked at Biological E in Hyderabad, India. In his role as Assistant General Manager, he led the commercial manufacturing of polysaccharide conjugate and protein-based Vaccines. Before that, he worked for Panacea Biotech, Sartorius, Sanofi and Krebs Biochemical Industries.

Dr Ramesh Mundlamuri is well-versed in cGMP, GLP, GDP and various regulatory bodies (WHO, EU, ROW, FDA, NRA). He also possesses extensive experience in the management of several vaccines, including polysaccharide vaccines, recombinant viral proteins, conventional vaccines and carrier protein.

Attributed to the BioE3 (Biotechnology for Economy, Employment and Environment) Policy, India's bioeconomy has seen exponential growth, ballooning from $10 billion in 2014 to a staggering $130 billion in 2024, with expectations to reach $300 billion by 2030. This policy also emphasizes the strategic objective of transitioning from chemical-based industries to sustainable bio-based models, promoting a circular bioeconomy. In this context, India has attracted numerous international biopharmaceutical companies to engage in business, which have absorbed a large number of local talents to better meet the demands of the domestic market. Dr Ramesh Mundlamuri joined Duoning Biotech (a comprehensive bioprocessing solutions provider) as the Head of Technology in 2023. In a discussion, he talked about the opportunities available in the Indian market and shared his insights and experiences in conducting bioprocessing business within the country.

We notice that most of Duoning's product offerings are centered around biomanufacturing, which may require customization or extensive testing. How do you provide support to local customers quickly and efficiently?

المزيد من القصص من Bio Spectrum

Bio Spectrum

Bio Spectrum

India's Pharma Reforms Target Global Credibility

The Indian government has introduced several measures to simplify drug approvals and support innovation.

time to read

9 mins

October 2025

Bio Spectrum

Bio Spectrum

How Waste Management Strategies Can Transform Indian Pharma Manufacturing

Sustainability will be a key success factor as India's pharmaceutical industry enters its next stage of expansion.

time to read

7 mins

October 2025

Bio Spectrum

Bio Spectrum

IASST synthesises new compound to combat aggressive breast cancer

A newly designed nitro-substituted organoselenium compound by Guwahati-based Institute of Advanced Study in Science and Technology (IASST), an autonomous institute under the Department of Science and Technology (DST), can reduce the invasiveness of aggressive triplenegative breast cancer cells by modulating various Se Se signalling pathways.

time to read

1 min

October 2025

Bio Spectrum

DPIIT signs MoU with Pfizer to strengthen healthcare innovation ecosystem

In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, has signed a Memorandum of Understanding (MoU) with Pfizer Limited.

time to read

1 min

October 2025

Bio Spectrum

Bio Spectrum

WHO unveils updated guideline on HIV service delivery

WHO has released an updated guideline to support integrated HIV service delivery, promote long-term adherence to antiretroviral therapy (ART), and improve the overall health and well-being of people living with HIV.

time to read

1 min

October 2025

Bio Spectrum

Scientists in Kolkata explore therapeutic potential of accessory proteins

A hidden protein that protects our cells from mechanical stress could provide a new direction to therapeutic strategies for diseases where protein stability under force is compromised like heart muscle disease or genetic disorders called laminopathies.

time to read

1 min

October 2025

Bio Spectrum

Bio Spectrum

US FDA advances rare disease drug development

The US Food and Drug Administration (FDA) has introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.

time to read

1 min

October 2025

Bio Spectrum

WHO updates list of essential medicines to include key cancer, diabetes treatments

The World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLC), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.

time to read

1 min

October 2025

Bio Spectrum

Agilent's MMR IHC Panel pharmDx (Dako Omnis) receives European IVDR Certification

Agilent Technologies Inc. has announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer.

time to read

1 min

October 2025

Bio Spectrum

Aodh Lifesciences gets support from TDB to redefine pneumonia treatment

The Technology Development Board (TDB), Department of Science and Technology, Government of India, has extended support to Aodh Lifesciences, a startup based in Hyderabad, for development of Indigenous Antibiotic Nebulisation Suspension for Pneumonia (AONEUM-04) and Antimicrobial Resistance (AMR).

time to read

1 min

October 2025

Listen

Translate

Share

-
+

Change font size